Analysts' outlook on Coherus BioSciences turns pessimistic w...
Analysts' outlook on Coherus BioSciences turns pessimistic with a significant cut to revenue estimates. Despite predicting faster revenue growth than the market, the drastic downgrade for next year's forecasts raises concerns about future performance.
Revenue Downgrade: Here's What Analysts Forecast For Coherus BioSciences, Inc. (NASDAQ:CHRS)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3196Followers
0Following
7970Visitors
Follow